Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, ai

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Bank of New York Mellon Corp lessened its holdings in Incyte Corporation (NASDAQ: INCY) by 1.3% duri

Fifth Third Bancorp boosted its stake in shares of Incyte Corporation (NASDAQ: INCY) by 145.2% in th

Andra AP fonden lessened its position in Incyte Corporation (NASDAQ: INCY) by 34.6% during the undef

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR developm

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth I

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data to Be Highlighted in Four Rapid Oral Presen

Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the pri

Incyte reports Phase 1/2 latarcibart data showing lower bleeding rates and favorable safety in patie

BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and raise

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enr

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its se

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raise

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Vega Therapeutics, a Wh

Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year.

Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS

Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average

Incyte Corporation remains a strong long pick, with a maintained 'Buy' rating and a 40% upside to a

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

UBS analyst Ashwani Verma maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price targ

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP)

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment opt

MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Opzelura®

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and rai

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrade

Top Wall Street analysts upgraded APA, INCY, COP, OVV, BWXT stocks with higher price targets. Check

Futures are trading mixed as we prepare to finish the last full week of the second quarter.

BMO Capital analyst Evan Seigerman upgrades Incyte (NASDAQ:INCY) from Underperform to Market Perf

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump

Large-cap stocks worst performers last week, including BEKE, RDDT, FUTU, JHX, INCY, NUE, BAH, XPEV,

  On Monday, 369 companies set new 52-week lows.

  On Thursday, 148 companies set new 52-week lows.

  Thursday's session saw 189 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

Stocks That Hit 52-Week Lows On Monday